JP6001074B2 - 新規なα−1アンチトリプシン変異体、その製造方法及び用途 - Google Patents
新規なα−1アンチトリプシン変異体、その製造方法及び用途 Download PDFInfo
- Publication number
- JP6001074B2 JP6001074B2 JP2014530581A JP2014530581A JP6001074B2 JP 6001074 B2 JP6001074 B2 JP 6001074B2 JP 2014530581 A JP2014530581 A JP 2014530581A JP 2014530581 A JP2014530581 A JP 2014530581A JP 6001074 B2 JP6001074 B2 JP 6001074B2
- Authority
- JP
- Japan
- Prior art keywords
- antitrypsin
- leu
- mutant
- lys
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title claims description 256
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title claims description 252
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title claims description 248
- 238000004519 manufacturing process Methods 0.000 title claims description 21
- 230000036252 glycation Effects 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 230000004927 fusion Effects 0.000 claims description 33
- 235000018102 proteins Nutrition 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 229940024606 amino acid Drugs 0.000 claims description 27
- 235000001014 amino acid Nutrition 0.000 claims description 27
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 24
- 229960001230 asparagine Drugs 0.000 claims description 24
- 235000009582 asparagine Nutrition 0.000 claims description 24
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 16
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 10
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 108010021466 Mutant Proteins Proteins 0.000 claims description 5
- 102000008300 Mutant Proteins Human genes 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 33
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 30
- 230000001965 increasing effect Effects 0.000 description 29
- 239000013598 vector Substances 0.000 description 29
- 230000002441 reversible effect Effects 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 239000008055 phosphate buffer solution Substances 0.000 description 18
- 210000003714 granulocyte Anatomy 0.000 description 17
- 102000051631 human SERPINA1 Human genes 0.000 description 17
- 102000016387 Pancreatic elastase Human genes 0.000 description 16
- 108010067372 Pancreatic elastase Proteins 0.000 description 16
- 230000004936 stimulating effect Effects 0.000 description 16
- 108010000521 Human Growth Hormone Proteins 0.000 description 15
- 102000002265 Human Growth Hormone Human genes 0.000 description 14
- 239000000854 Human Growth Hormone Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 14
- 239000002753 trypsin inhibitor Substances 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 101710081722 Antitrypsin Proteins 0.000 description 9
- 230000001475 anti-trypsic effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 210000004102 animal cell Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000006167 equilibration buffer Substances 0.000 description 6
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- 108010025306 histidylleucine Proteins 0.000 description 6
- 108010017391 lysylvaline Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010073969 valyllysine Proteins 0.000 description 6
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000012453 sprague-dawley rat model Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- AXFMEGAFCUULFV-BLFANLJRSA-N (2s)-2-[[(2s)-1-[(2s,3r)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid Chemical compound CC[C@@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AXFMEGAFCUULFV-BLFANLJRSA-N 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- FVSOUJZKYWEFOB-KBIXCLLPSA-N Ala-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N FVSOUJZKYWEFOB-KBIXCLLPSA-N 0.000 description 3
- LTSBJNNXPBBNDT-HGNGGELXSA-N Ala-His-Gln Chemical compound N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)O LTSBJNNXPBBNDT-HGNGGELXSA-N 0.000 description 3
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 description 3
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 3
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 3
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 3
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 3
- YFHATWYGAAXQCF-JYJNAYRXSA-N Arg-Pro-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YFHATWYGAAXQCF-JYJNAYRXSA-N 0.000 description 3
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 3
- CTQIOCMSIJATNX-WHFBIAKZSA-N Asn-Gly-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O CTQIOCMSIJATNX-WHFBIAKZSA-N 0.000 description 3
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 3
- PHJPKNUWWHRAOC-PEFMBERDSA-N Asn-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PHJPKNUWWHRAOC-PEFMBERDSA-N 0.000 description 3
- XLZCLJRGGMBKLR-PCBIJLKTSA-N Asn-Ile-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XLZCLJRGGMBKLR-PCBIJLKTSA-N 0.000 description 3
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 3
- RTFWCVDISAMGEQ-SRVKXCTJSA-N Asn-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N RTFWCVDISAMGEQ-SRVKXCTJSA-N 0.000 description 3
- PUUPMDXIHCOPJU-HJGDQZAQSA-N Asn-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O PUUPMDXIHCOPJU-HJGDQZAQSA-N 0.000 description 3
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 3
- BKXPJCBEHWFSTF-ACZMJKKPSA-N Asp-Gln-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O BKXPJCBEHWFSTF-ACZMJKKPSA-N 0.000 description 3
- VILLWIDTHYPSLC-PEFMBERDSA-N Asp-Glu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VILLWIDTHYPSLC-PEFMBERDSA-N 0.000 description 3
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 3
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 3
- GWWSUMLEWKQHLR-NUMRIWBASA-N Asp-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O GWWSUMLEWKQHLR-NUMRIWBASA-N 0.000 description 3
- XAPPCWUWHNWCPQ-PBCZWWQYSA-N Asp-Thr-His Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O XAPPCWUWHNWCPQ-PBCZWWQYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 3
- NSNUZSPSADIMJQ-WDSKDSINSA-N Gln-Gly-Asp Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NSNUZSPSADIMJQ-WDSKDSINSA-N 0.000 description 3
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 3
- CAXXTYYGFYTBPV-IUCAKERBSA-N Gln-Leu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CAXXTYYGFYTBPV-IUCAKERBSA-N 0.000 description 3
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 3
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 3
- ATRHMOJQJWPVBQ-DRZSPHRISA-N Glu-Ala-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ATRHMOJQJWPVBQ-DRZSPHRISA-N 0.000 description 3
- IRDASPPCLZIERZ-XHNCKOQMSA-N Glu-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N IRDASPPCLZIERZ-XHNCKOQMSA-N 0.000 description 3
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 3
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 3
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 3
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 3
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 3
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 description 3
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 3
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 3
- PHONXOACARQMPM-BQBZGAKWSA-N Gly-Ala-Met Chemical compound [H]NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O PHONXOACARQMPM-BQBZGAKWSA-N 0.000 description 3
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 3
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 3
- QGDOOCIPHSSADO-STQMWFEESA-N Gly-Met-Phe Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QGDOOCIPHSSADO-STQMWFEESA-N 0.000 description 3
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 3
- FOKISINOENBSDM-WLTAIBSBSA-N Gly-Thr-Tyr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FOKISINOENBSDM-WLTAIBSBSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 3
- ZJSMFRTVYSLKQU-DJFWLOJKSA-N His-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N ZJSMFRTVYSLKQU-DJFWLOJKSA-N 0.000 description 3
- QSLKWWDKIXMWJV-SRVKXCTJSA-N His-Cys-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N QSLKWWDKIXMWJV-SRVKXCTJSA-N 0.000 description 3
- AKEDPWJFQULLPE-IUCAKERBSA-N His-Glu-Gly Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O AKEDPWJFQULLPE-IUCAKERBSA-N 0.000 description 3
- OWYIDJCNRWRSJY-QTKMDUPCSA-N His-Pro-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O OWYIDJCNRWRSJY-QTKMDUPCSA-N 0.000 description 3
- KDDKJKKQODQQBR-NHCYSSNCSA-N His-Val-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N KDDKJKKQODQQBR-NHCYSSNCSA-N 0.000 description 3
- HZMLFETXHFHGBB-UGYAYLCHSA-N Ile-Asn-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZMLFETXHFHGBB-UGYAYLCHSA-N 0.000 description 3
- UDLAWRKOVFDKFL-PEFMBERDSA-N Ile-Asp-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N UDLAWRKOVFDKFL-PEFMBERDSA-N 0.000 description 3
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 3
- QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 3
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 3
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 3
- STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 description 3
- RFUBXQQFJFGJFV-GUBZILKMSA-N Leu-Asn-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RFUBXQQFJFGJFV-GUBZILKMSA-N 0.000 description 3
- BOFAFKVZQUMTID-AVGNSLFASA-N Leu-Gln-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N BOFAFKVZQUMTID-AVGNSLFASA-N 0.000 description 3
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 3
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 3
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 3
- IBSGMIPRBMPMHE-IHRRRGAJSA-N Leu-Met-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O IBSGMIPRBMPMHE-IHRRRGAJSA-N 0.000 description 3
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 3
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 3
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 3
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 3
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 3
- PYFNONMJYNJENN-AVGNSLFASA-N Lys-Lys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N PYFNONMJYNJENN-AVGNSLFASA-N 0.000 description 3
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 3
- ODTZHNZPINULEU-KKUMJFAQSA-N Lys-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N ODTZHNZPINULEU-KKUMJFAQSA-N 0.000 description 3
- LNMKRJJLEFASGA-BZSNNMDCSA-N Lys-Phe-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LNMKRJJLEFASGA-BZSNNMDCSA-N 0.000 description 3
- GIKFNMZSGYAPEJ-HJGDQZAQSA-N Lys-Thr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O GIKFNMZSGYAPEJ-HJGDQZAQSA-N 0.000 description 3
- XGZDDOKIHSYHTO-SZMVWBNQSA-N Lys-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 XGZDDOKIHSYHTO-SZMVWBNQSA-N 0.000 description 3
- JACAKCWAOHKQBV-UWVGGRQHSA-N Met-Gly-Lys Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN JACAKCWAOHKQBV-UWVGGRQHSA-N 0.000 description 3
- BEZJTLKUMFMITF-AVGNSLFASA-N Met-Lys-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCNC(N)=N BEZJTLKUMFMITF-AVGNSLFASA-N 0.000 description 3
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 3
- JNRFYJZCMHHGMH-UBHSHLNASA-N Phe-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JNRFYJZCMHHGMH-UBHSHLNASA-N 0.000 description 3
- LBSARGIQACMGDF-WBAXXEDZSA-N Phe-Ala-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 LBSARGIQACMGDF-WBAXXEDZSA-N 0.000 description 3
- KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 3
- KPEIBEPEUAZWNS-ULQDDVLXSA-N Phe-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KPEIBEPEUAZWNS-ULQDDVLXSA-N 0.000 description 3
- OSBADCBXAMSPQD-YESZJQIVSA-N Phe-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N OSBADCBXAMSPQD-YESZJQIVSA-N 0.000 description 3
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 3
- AUJWXNGCAQWLEI-KBPBESRZSA-N Phe-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AUJWXNGCAQWLEI-KBPBESRZSA-N 0.000 description 3
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 description 3
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 3
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 3
- XYAFCOJKICBRDU-JYJNAYRXSA-N Pro-Phe-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O XYAFCOJKICBRDU-JYJNAYRXSA-N 0.000 description 3
- HRIXMVRZRGFKNQ-HJGDQZAQSA-N Pro-Thr-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HRIXMVRZRGFKNQ-HJGDQZAQSA-N 0.000 description 3
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 3
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 3
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 3
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 3
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 3
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 3
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 3
- HAUVENOGHPECML-BPUTZDHNSA-N Ser-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 HAUVENOGHPECML-BPUTZDHNSA-N 0.000 description 3
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 3
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 description 3
- QNCFWHZVRNXAKW-OEAJRASXSA-N Thr-Lys-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QNCFWHZVRNXAKW-OEAJRASXSA-N 0.000 description 3
- BCYUHPXBHCUYBA-CUJWVEQBSA-N Thr-Ser-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O BCYUHPXBHCUYBA-CUJWVEQBSA-N 0.000 description 3
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 3
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 3
- SPIFGZFZMVLPHN-UNQGMJICSA-N Thr-Val-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SPIFGZFZMVLPHN-UNQGMJICSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- JHORGUYURUBVOM-KKUMJFAQSA-N Tyr-His-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O JHORGUYURUBVOM-KKUMJFAQSA-N 0.000 description 3
- AZZLDIDWPZLCCW-ZEWNOJEFSA-N Tyr-Ile-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O AZZLDIDWPZLCCW-ZEWNOJEFSA-N 0.000 description 3
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 3
- QGFPYRPIUXBYGR-YDHLFZDLSA-N Val-Asn-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N QGFPYRPIUXBYGR-YDHLFZDLSA-N 0.000 description 3
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 3
- ZXAGTABZUOMUDO-GVXVVHGQSA-N Val-Glu-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZXAGTABZUOMUDO-GVXVVHGQSA-N 0.000 description 3
- CHWRZUGUMAMTFC-IHRRRGAJSA-N Val-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CNC=N1 CHWRZUGUMAMTFC-IHRRRGAJSA-N 0.000 description 3
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 3
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 3
- KISFXYYRKKNLOP-IHRRRGAJSA-N Val-Phe-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N KISFXYYRKKNLOP-IHRRRGAJSA-N 0.000 description 3
- WANVRBAZGSICCP-SRVKXCTJSA-N Val-Pro-Met Chemical compound CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C)C(O)=O WANVRBAZGSICCP-SRVKXCTJSA-N 0.000 description 3
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 3
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 3
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 3
- 108010005233 alanylglutamic acid Proteins 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 108010077245 asparaginyl-proline Proteins 0.000 description 3
- 108010068265 aspartyltyrosine Proteins 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 108010085059 glutamyl-arginyl-proline Proteins 0.000 description 3
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 3
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 3
- 108010081551 glycylphenylalanine Proteins 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 3
- 108010053037 kyotorphin Proteins 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 108010054155 lysyllysine Proteins 0.000 description 3
- 108010085203 methionylmethionine Proteins 0.000 description 3
- 108010068488 methionylphenylalanine Proteins 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 108010024607 phenylalanylalanine Proteins 0.000 description 3
- 108010012581 phenylalanylglutamate Proteins 0.000 description 3
- 108010051242 phenylalanylserine Proteins 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 108010025488 pinealon Proteins 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108010061238 threonyl-glycine Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- QPRZKNOOOBWXSU-CIUDSAMLSA-N Glu-Asp-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N QPRZKNOOOBWXSU-CIUDSAMLSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- CZWANIQKACCEKW-CYDGBPFRSA-N Ile-Pro-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)O)N CZWANIQKACCEKW-CYDGBPFRSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- IUXGJEIKJBYKOO-SRVKXCTJSA-N Ser-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N IUXGJEIKJBYKOO-SRVKXCTJSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 102200075245 rs118204104 Human genes 0.000 description 2
- 102220094401 rs749548566 Human genes 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- XPWLQCVMYWPSKT-UHFFFAOYSA-N 4-(4-amino-2,5-dimethylphenyl)-2,6-dimethylaniline Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1C XPWLQCVMYWPSKT-UHFFFAOYSA-N 0.000 description 1
- GVUGADOWXGKRAE-SRVKXCTJSA-N 4-[[(2s)-1-[[(2s)-1-[[(2s)-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GVUGADOWXGKRAE-SRVKXCTJSA-N 0.000 description 1
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- YYOBUPFZLKQUAX-FXQIFTODSA-N Glu-Asn-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YYOBUPFZLKQUAX-FXQIFTODSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- IPYVXYDYLHVWHU-GMOBBJLQSA-N Ile-Asn-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N IPYVXYDYLHVWHU-GMOBBJLQSA-N 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001507 asparagine derivatives Chemical class 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011086 glassine Substances 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940099982 prolastin Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- -1 respectively Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940032528 zemaira Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Marine Sciences & Fisheries (AREA)
Description
1−1. 発現ベクターpAV1の製造
本発明に必要な発現ベクタークローニングは、母ベクターであるpSGHV0(GenBank Accession No. AF285183)を利用して産業で使用可能に目的に合わせて改良して開発したpAV1ベクターを利用した。母ベクターは、大腸菌のようなバクテリアを利用してヒト由来のタンパク質を発現させる場合には、タンパク質が細胞内で過剰発現されるが、大部分活性を有しないので、動物細胞を利用した場合には、細胞外に生理活性を有した目的タンパク質を高濃度で発現させる特性を有しているので、生理活性を有したタンパク質を手軽く精製する目的で製作された研究用ベクターである。しかし、産業で生産用で使用するためには、いろいろに制限があるので、pSGHV0ベクターの最大の長所である発現量が高い点を生産に利用するために、産業で使用可能に改良した。
α−1アンチトリプシンベクターを製造するために、hMU001448(KRIBB)を鋳型としたα−1アンチトリプシン(M3)遺伝子をpAV1ベクターにクローニングしてα−1アンチトリプシンベクター(pT003)を製造した。具体的には、hMU001448(KRIBB)を鋳型として、2個のプライマーであるXhoAT正方向プライマー(5'−CCC TCC TCG AGA ATG CCG TCT TCT GTC TCG−3'、配列番号1)とATNot逆方向プライマー(5'−GGG CCC GCG GCC GCA GTT ATT TTT GGG TGG G−3'、配列番号2)を利用してPCRで増幅した。前記増幅されたヌクレオチドを、末端に存在する二つの制限酵素であるXhoIと NotIで切断し、XhoI/NotI切断部を有している発現ベクターpAV1と接合してα−1アンチトリプシンベクター(pT003、配列番号39)を製造した。前記α−1アンチトリプシンベクター(pT003)の模式図は、図1に示した。
糖化部位が追加された多くのα−1アンチトリプシン変異体を製造するために、前記実施例1−2で製造したα−1アンチトリプシンベクター(pT003)を鋳型として、下記表1に記載された各々の2個の正方向プライマーと逆方向プライマーと変異体生成キット(Enzynomix、EZchangeTM Site−Directed Mutagenesis Kit)を利用してα−1アンチトリプシン変異体を製造した。α−1アンチトリプシン変異体の配列と位置は、図2に示した。
α−1アンチトリプシンベクターを製造するために、pEAT8(encoding a1−AT(M2) cDNA)を鋳型としたα−1アンチトリプシン遺伝子をpAV1ベクターにクローニングして、α−1アンチトリプシンベクター(pT006)を製造した。具体的には、pEAT8(encoding a1−AT(M2) cDNA)を鋳型として、2個のプライマーであるXhoAT正方向プライマー(5'−CCC TCC TCG AGA ATG CCG TCT TCT GTC TCG−3'、配列番号1)とATNot逆方向プライマー(5'−GGG CCC GCG GCC GCA GTT ATT TTT GGG TGG G−3'、配列番号2)を利用してPCRで増幅した。前記増幅されたヌクレオチドを末端に存在する二つの制限酵素であるXhoIと NotIで切断し、XhoI/NotI切断部を有している発現ベクターpAV1と接合してα−1アンチトリプシンベクター(pT006、配列番号40)を製造した。
糖化部位が追加されたα−1アンチトリプシン(M2)変異体を製造するために、前記実施例1−4で製造したα−1アンチトリプシンベクター(pT006)を鋳型として、2個のプライマーである正方向プライマー(配列番号5)と逆方向プライマー(配列番号6)を利用して、変異体生成キット(Enzynomix、EZchangeTM Site−Directed Mutagenesis Kit)を利用してα−1アンチトリプシン(M2)変異体ベクター(AT9N(M2))を製造した。製造されたα−1アンチトリプシン変異体のアミノ酸配列は、配列番号42に示した。
α−1アンチトリプシン変異体の二重体を製造するために、α−1アンチトリプシン変異体は、pAT9N(subtype M2)を使用した。二重体ベクターを製造するために、pAT9N(M2)を鋳型として、2個のプライマーであるXhoAT正方向プライマー2(5'−GGG CCC CTC GAG GCC ACC ATG CCG TCT TCT GTC TCG TGG GGC ATC CTC CTG CTG GCA GGC CTG TGC TGC CTG GTC CCT GTC TCC CTG GCT GAA GAT CCC CAG GGA −3'、配列番号31)とATBam逆方向プライマー2(5'−GGG GGG ATC CTC TTT TTG GGT GGG ATT CAC −3'、配列番号32)を利用してPCRで増幅した。前記増幅されたヌクレオチドを末端に存在する二つの制限酵素であるXhoIと BamHIで切断し、XhoI/BamHI切断部を有している発現ベクターpAT9N(M2)と接合してα−1アンチトリプシン二重体ベクター(pAT9N(M2)−AT9N(M2))を製造した。
チャイニーズハムスター卵巣細胞(CHO−K1)を利用して、前記実施例1−2、3、4、5及び6で製造したα−1アンチトリプシン(T003、T006)とその変異体及び二重体のタンパク質発現を確認した。CHO−K1は、10% FBS(Fetal Bovine Serum)と抗生剤を含んだDMEM(Dulbecco's Modified Eagle Media)に5%CO2と37℃条件で培養して維持した。α−1アンチトリプシン及びその変異体発現ベクターを導入する一日前、100mm培養皿に細胞を5×106 cellsで接種して培養し、FBSと抗生剤がない800μLのDMEMと10μgのα−1アンチトリプシンとその変異体及び二重体の発現ベクター各々を混合して常温で1分間維持した後、20μgのPEI(Polyethylenimine、linear、Polysciences Inc.(Cat. no:23966, MW〜25,000)と混合して10〜15分程度の常温で放置した。この時、一日の前に培養した細胞をPBSで洗浄して新しい培養液の6mLのDMEMを添加した。10〜15分後、常温に放置したα−1アンチトリプシンとその変異体及び二重体の発現ベクターを各々前記培養皿に添加した。翌日、PBSで洗浄してFBSのないIMDM(Cat. No 12200−028, Gibco, Iscove's Modified Dulbecco's Medium)培地を添加してタンパク質発現を確認した。
前記実施例1−7により発現されたα−1アンチトリプシンとその変異体及び二重体は、下記のように精製した。具体的には、細胞培養液に分泌されたα−1アンチトリプシンとその変異体及び二重体を精製するために、培養液を遠心分離して細胞を除去した後、上清液のみを取り、細胞上清液を平衡緩衝溶液(20mM sodium phosphate、pH8.0)で希釈した。その後、前記平衡緩衝溶液で希釈された細胞上清液を平衡緩衝溶液で平衡化されたQ−Sepharose(GE Healthcare、アメリカ)コラムに注入して平衡緩衝溶液で充分に洗浄した後、塩化ナトリウムの濃度を増加(0〜400mM NaCl、20mM sodium phosphate、pH8.0)させてタンパク質を溶出させた。溶出されたタンパク質を平衡緩衝溶液(トリス50mM、塩化ナトリウム0.15M、pH7.5)で平衡化されたAlpha−1 Antitrypsin Select(GE Healthcare、アメリカ)コラムに注入した後、平衡緩衝溶液で充分に洗浄してMgCl2の濃度を増加させてタンパク質を溶出させた。前記溶液をリン酸塩緩衝溶液で透析した後、Vivaspin20(GE Healthcare、アメリカ)を使用して濃縮して、最終的に、高純度で精製されたタンパク質を得た。前記精製されたα−1アンチトリプシンとその変異体及び二重体のSDS−PAGE結果は、図3に示した。
ヒト成長ホルモン/α−1アンチトリプシン変異体(AT9N)の融合体を製造するために、α−1アンチトリプシン変異体ではpAT9N(subtype M2)を使用した。融合体ベクターを製造するために、ヒト成長ホルモン遺伝子(IOH45734(invitrogen))を鋳型として、2個のプライマーあるXhoGH正方向プライマー(5'−GGG CCC CTC GAG GCC ACC ATG GCT ACA GGC TCC CGG−3'、配列番号33)とGHBam逆方向プライマー(5'−GGG GGG ATC CTC GAA GCC ACA GCT GCC CTC −3'、配列番号34)を利用してPCRで増幅した。前記増幅されたヌクレオチドを末端に存在する二つの制限酵素であるXhoIとBamHIで切断し、XhoI/BamHI切断部を有している発現ベクターpAT9N(M2)と接合してヒト成長ホルモン/α−1アンチトリプシン変異体融合体ベクター(phGH−AT9N(M2)、配列番号43)を製造した。
3−1. α−1アンチトリプシン二重変異体の製造
実施例1−5と同一な方法で製造されたα−1アンチトリプシン変異体(AT9N)ベクターを鋳型として、下記2個のプライマーの正方向プライマー(5'−CCA TGT TTT TAG AGG CCA TAA ACA TGT CTA TCC CCC CC−3'、配列番号35)と逆方向プライマー(5'−GGG GGG GAT AGA CAT GTT TAT GGC CTC TAA AAA CAT GG−3'、配列番号36)と変異体生成キット(Enzynomix、EZchangeTM Site−Directed Mutagenesis Kit)を利用して、α−1アンチトリプシンN−末端の9番位置のグルタミン(glutamine)がアスパラギン(asparagine)に置換されて、また357番位置のプロリン(proline)がアスパラギン(asparagine)に置換されたα−1アンチトリプシン二重変異体を含むベクターpT004N(Q9N、P357N)を製造した。製造されたα−1アンチトリプシン二重変異体のアミノ酸配列は、配列番号44に示した。
顆粒球刺激因子/α−1アンチトリプシン二重変異体の融合体を製造するために、実施例3−1の方法で製造されたα−1アンチトリプシン二重変異体を含むpT004N(Q9N、P357N)を使用した。融合体ベクターを製造するために、顆粒球刺激因子(Granulocyte Colony Stimulating Factor, IHS1380-97652343(Open biosystems))を鋳型として、2個のプライマーであるXhoCSF正方向プライマー(5'−GGG CCC CTC GAG ATG GCT GGA CCT GCC ACC−3'、配列番号37)とCSFBam逆方向プライマー(5'−GGG GGG ATC CTC GGG CTG GGC AAG GTG GCG−3'、配列番号38)を利用してPCRで増幅した。前記増幅されたヌクレオチドを末端に存在する二つの制限酵素であるXhoIとBamHIで切断し、XhoI/BamHI切断部を有している発現ベクターpT004Nと接合して顆粒球刺激因子/α−1アンチトリプシン二重変異体融合体ベクター(pT603N、配列番号45)を製造した。以後、製造された前記ベクター(pT603N)を利用して実施例1−7及び1−8と同一な方法で顆粒球刺激因子/α−1アンチトリプシン二重変異体を発現及び精製した。
血漿由来のα−1アンチトリプシンと本発明のチャイニーズハムスター卵巣細胞で製造したα−1アンチトリプシンの薬物動態を確認するために、下記のような実験を実行した。
本発明によるα−1アンチトリプシン及びその変異体のエラスターゼ活性抑制効果を確認するために、下記のような実験を実行した。
[E]T=酵素の初期濃度(Initial concentration of enzyme)
[I]T=阻害剤の初期濃度(Initial concentration of inhibitor)
[E]f=[E]T×(Atest/Acontrol)
[EI]=[E]T−[E]f=[E]T×(1−Atest/Acontrol)
[I]f=[I]T−[EI]
A=slope of t(measurement time)vs absorbance
本発明によるヒト成長ホルモン/α−1アンチトリプシン変異体の融合体の薬物動態を確認するために、下記のような実験を実行した。実験動物としてSprague−Dawleyラット(rat)を使用した。ヒト成長ホルモン投与群には、3匹を割り当て、融合体投与群には、5匹を割り当てた。Sprague−Dawleyラットに前記実施例2で製造したヒト成長ホルモン/α−1アンチトリプシン融合体を各々ラットkg当たり720μgの投与量で皮下注射した。希釈液は、リン酸塩緩衝溶液を使用し、0、1、2、4、8、12、16、24、30、48時間後に採血して遠心分離して血清を得た。対照群では、ヒト成長ホルモンであるScitropin(SciGen, シンガポール)をラットkg当たり200μgの投与量で皮下注射した。希釈液は、リン酸塩緩衝溶液を使用し、0、0.33、1、2、5、8、12、18、24、30、48時間後に採血して遠心離して血清を得た。各試料に対しては、次のような酵素免疫分析方法を利用して分析した。ヒト成長ホルモンに対するモノクローナル抗体(Medix Biochemica, フィンランド)をリン酸塩緩衝溶液に1〜5μg/mLの濃度で希釈して100μLを96ウェルプレート(Nunc, デンマーク)に分注した後、常温で15〜18時間の間放置した。ウェルプレートに付着しなく残っている抗体を除去した後、1%ウシ血清アルブミンが溶解されたリン酸塩緩衝溶液250μLを分注して常温で2時間放置させて、洗浄溶液(0.05%ツイン20、リン酸塩緩衝溶液)で3回洗浄して溶液を除去した。試料は、1%ウシ血清アルブミンが溶解されたリン酸塩緩衝溶液で希釈し、96ウェルプレートに添加して常温で2時間の間反応させた。96ウェルプレートを洗浄溶液で5回洗浄した後、sulfo−NHS−biotin(Pierce biotechnology、アメリカ)を利用して接合させたヒト成長ホルモンモノクローナル抗体−ビオチン接合体を希釈溶液で希釈して96ウェルプレートに100μLずつ分注した。引き継いで、プレートを常温で2時間反応させた後、洗浄溶液で5回洗浄し、ストレプトアビジン−HRP溶液を加えて常温で30分間反応させた。洗浄溶液で5回洗浄してTMB(3,3',5,5'−テトラメチルベンジジン)と過酸化水素水発色溶液100μLを各ウェルに添加した後、暗所で30分間反応させた。1M硫酸100μLを各ウェルに添加して反応を終了させて、VersaMax microplate reader(Molecular Device、アメリカ)で450nmで吸光度を測定した。各試料の定量値は、標準物質に対する標準曲線を作成して回帰分析を通じて求めた。
本発明による顆粒球刺激因子/α−1アンチトリプシン二重変異体融合体の薬物動態を確認するために、下記のような実験を実行した。実験動物として、Sprague−Dawleyラット(rat)を使用した。顆粒球刺激因子投与群には、5匹を割り当て、融合体投与群には、3匹を各々割り当てた。Sprague−Dawleyラットに実施例3の方法で製造した顆粒球刺激因子/α−1アンチトリプシン二重変異体融合体(pT603N)を各々ラットkg当たり340μgの投与量で皮下注射した。希釈液では、リン酸塩緩衝溶液(PBS:phosphate buffered saline)を使用した。皮下注射した後、0、1、2、4、8、12、16、24、36、48、60及び72時間後に採血して遠心分離して血清を収得した。対照群では、顆粒球刺激因子であるグラシン(Grasin, Filgrastim)をリン酸塩緩衝溶液で希釈してラットkg当たり100μgの投与量で皮下注射し、0、0.5、1、2、4、8、12、16、24、36及び48時間後に採血して遠心分離して血清を収得した。各試料に対しては、下記のような酵素免疫分析方法(ELISA)を利用して分析した。顆粒球刺激因子に対するモノクローナル抗体(R&D systems)をリン酸塩緩衝溶液に1〜10μg/mLの濃度で希釈して100μLずつ96ウェルプレート(Nunc、デンマーク)に分注した後、常温で15〜18時間の間放置した。以後、ウェルプレートに付着しなくて残っている抗体を除去した後、1%ウシ血清アルブミンが溶解されたリン酸塩緩衝溶液250μLを分注して常温で2時間放置させて、洗浄溶液(0.05%ツイン20、リン酸塩緩衝溶液)で3回洗浄して溶液を除去した。試料は、1%ウシ血清アルブミンが溶解されたリン酸塩緩衝溶液で希釈し、96ウェルプレートに添加して常温で2時間の間反応させた。96ウェルプレートを洗浄溶液で5回洗浄した後、顆粒球刺激因子であるポリクローナル抗体−ビオチン接合体(R&D systems)を希釈溶液で希薄して96ウェルプレートに100μLずつ分注した。引き継いで、プレートを常温で2時間反応させた後、洗浄溶液で5回洗浄してストレプトアビジン−HRP溶液を加えて常温で30分間反応させた後、洗浄溶液で5回洗浄してTMB(3,3',5,5'−テトラメチルベンジジン)と過酸化水素水発色溶液100μLを各ウェルに添加して暗所で30分間反応させた。以後、1M硫酸溶液100μLを各ウェルに添加して反応を終了させて、VersaMax microplate reader(Molecular Device、アメリカ)で450nmで吸光度を測定した。各試料の定量値は、標準物質に対する標準曲線を作成して回帰分析を通じて求めた。本発明による顆粒球刺激因子/α−1アンチトリプシン変異体の融合体の薬物動態グラフは、図10に示した。
<120> New alpha-1 antitrypsin variant, method for producing the same and use thereof
<130> J-P14027
<150> KR 10-2011-0092819
<151> 2011-09-15
<150> KR 10-2012-0058998
<151> 2012-06-01
<160> 45
<170> KopatentIn 2.0
<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> A1AT forward primer 1
<400> 1
ccctcctcga gaatgccgtc ttctgtctcg 30
<210> 2
<211> 31
<212> DNA
<213> Artificial Sequence
<220>
<223> A1AT reverse primer 1
<400> 2
gggcccgcgg ccgcagttat ttttgggtgg g 31
<210> 3
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Q4N forward primer
<400> 3
aacggaactg ctgcccagaa gacagataca 30
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Q4N reverse primer
<400> 4
gggatcctca gccagggaga c 21
<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Q9N forward primer
<400> 5
aacaagacag atacatccca c 21
<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Q9N reverse primer
<400> 6
ggcagcatct ccctggggat c 21
<210> 7
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> D12N forward primer
<400> 7
aatacaaccc accatgatca ggatcac 27
<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> D12N reverse primer
<400> 8
tgtcttctgg gcagcatctc c 21
<210> 9
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> I26T forward primer
<400> 9
actaccccca acctggctg 19
<210> 10
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> I26T reverse primer
<400> 10
cttgttgaag gttgggtgat cc 22
<210> 11
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> A31T forward primer
<400> 11
actgagttcg ccttcagcct atac 24
<210> 12
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> A31T reverse primer
<400> 12
caggttgggg gtgatcttgt tg 22
<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> L66N forward primer
<400> 13
aacgggacca aggctgacac 20
<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> L66N reverse primer
<400> 14
ggagagcatt gcaaaggctg ta 22
<210> 15
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> A70N forward primer
<400> 15
aacgacactc acgatgaaat cctg 24
<210> 16
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> A70N reverse primer
<400> 16
cttggtcccc agggagag 18
<210> 17
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> G148N forward primer
<400> 17
aacgacaccg aagaggccaa g 21
<210> 18
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> G148N reverse primer
<400> 18
gaagttgaca gtgaaggctt ctg 23
<210> 19
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> G148T forward primer
<400> 19
actgacaccg aagaggccaa g 21
<210> 20
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> G148T reverse primer
<400> 20
gaagttgaca gtgaaggctt ctg 23
<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> R178N forward primer
<400> 21
aacgacacag tttttgctct ggtg 24
<210> 22
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> R178N reverse primer
<400> 22
gtcaagctcc ttgaccaaat cca 23
<210> 23
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> K201N forward primer
<400> 23
aacgacaccg aggaagagga c 21
<210> 24
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> K201N reverse primer
<400> 24
gacttcaaag ggtctctccc att 23
<210> 25
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Q212N forward primer
<400> 25
aacgtgacca ccgtgaaggt g 21
<210> 26
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Q212N reverse primer
<400> 26
gtccacgtgg aagtcctctt c 21
<210> 27
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> E266N forward primer
<400> 27
aacctcaccc acgatatcat cac 23
<210> 28
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> E266N reverse primer
<400> 28
attttccagg tgctgtagtt tccc 24
<210> 29
<211> 16
<212> DNA
<213> Artificial Sequence
<220>
<223> K343N forward primer
<400> 29
aacgggactg aagctg 16
<210> 30
<211> 16
<212> DNA
<213> Artificial Sequence
<220>
<223> K343N reverse primer
<400> 30
ctcgtcgatg gtcagc 16
<210> 31
<211> 105
<212> DNA
<213> Artificial Sequence
<220>
<223> A1AT forward primer 2
<400> 31
gggcccctcg aggccaccat gccgtcttct gtctcgtggg gcatcctcct gctggcaggc 60
ctgtgctgcc tggtccctgt ctccctggct gaagatcccc aggga 105
<210> 32
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> A1AT reverse primer 2
<400> 32
ggggggatcc tctttttggg tgggattcac 30
<210> 33
<211> 36
<212> DNA
<213> Artificial Sequence
<220>
<223> hGH forward primer
<400> 33
gggcccctcg aggccaccat ggctacaggc tcccgg 36
<210> 34
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> hGH reverse primer
<400> 34
ggggggatcc tcgaagccac agctgccctc 30
<210> 35
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> P357N forward primer
<400> 35
ccatgttttt agaggccata aacatgtcta tccccccc 38
<210> 36
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> P357N reverse primer
<400> 36
gggggggata gacatgttta tggcctctaa aaacatgg 38
<210> 37
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> XhoCSF forward primer
<400> 37
gggcccctcg agatggctgg acctgccacc 30
<210> 38
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> CSFBam reverse primer
<400> 38
ggggggatcc tcgggctggg caaggtggcg 30
<210> 39
<211> 1182
<212> DNA
<213> Artificial Sequence
<220>
<223> pT003
<400> 39
gaggatcccc agggagatgc tgcccagaag acagatacat cccaccatga tcaggatcac 60
ccaaccttca acaagatcac ccccaacctg gctgagttcg ccttcagcct ataccgccag 120
ctggcacacc agtccaacag caccaatatc ttcttctccc cagtgagcat cgctacagcc 180
tttgcaatgc tctccctggg gaccaaggct gacactcacg atgaaatcct ggagggcctg 240
aatttcaacc tcacggagat tccggaggct cagatccatg aaggcttcca ggaactcctc 300
cgtaccctca accagccaga cagccagctc cagctgacca ccggcaatgg cttgttcctc 360
agcgagggcc tgaagctagt ggataagttt ttggaggatg ttaaaaagtt gtaccactca 420
gaagccttca ctgtcaactt cggggacacc gaagaggcca agaaacagat caacgattac 480
gtggagaagg gtactcaagg gaaaattgtg gatttggtca aggagcttga cagagacaca 540
gtttttgctc tggtgaatta catcttcttt aaaggcaaat gggagagacc ctttgaagtc 600
aaggacaccg aggaagagga cttccacgtg gaccaggtga ccaccgtgaa ggtgcctatg 660
atgaagcgtt taggcatgtt taacatccag cactgtaaga agctgtccag ctgggtgctg 720
ctgatgaaat acctgggcaa tgccaccgcc atcttcttcc tgcctgatga ggggaaacta 780
cagcacctgg aaaatgaact cacccacgat atcatcacca agttcctgga aaatgaagac 840
agaaggtctg ccagcttaca tttacccaaa ctgtccatta ctggaaccta tgatctgaag 900
agcgtcctgg gtcaactggg catcactaag gtcttcagca atggggctga cctctccggg 960
gtcacagagg aggcacccct gaagctctcc aaggccgtgc ataaggctgt gctgaccatc 1020
gacgagaaag ggactgaagc tgctggggcc atgtttttag aggccatacc catgtctatc 1080
ccccccgagg tcaagttcaa caaacccttt gtcttcttaa tgattgacca aaataccaag 1140
tctcccctct tcatgggaaa agtggtgaat cccacccaaa aa 1182
<210> 40
<211> 1182
<212> DNA
<213> Artificial Sequence
<220>
<223> pT006
<400> 40
gaggatcccc agggagatgc tgcccagaag acagatacat cccaccatga tcaggatcac 60
ccaaccttca acaagatcac ccccaacctg gctgagttcg ccttcagcct ataccgccag 120
ctggcacacc agtccaacag caccaatatc ttcttctccc cagtgagcat cgctacagcc 180
tttgcaatgc tctccctggg gaccaaggct gacactcacg atgaaatcct ggagggcctg 240
aatttcaacc tcacggagat tccggaggct cagatccatg aaggcttcca ggaactcctc 300
cataccctca accagccaga cagccagctc cagctgacca ccggcaatgg cctgttcctc 360
agcgagggcc tgaagctagt ggataagttt ttggaggatg ttaaaaagtt gtaccactca 420
gaagccttca ctgtcaactt cggggacacc gaagaggcca agaaacagat caacgattac 480
gtggagaagg gtactcaagg gaaaattgtg gatttggtca aggagcttga cagagacaca 540
gtttttgctc tggtgaatta catcttcttt aaaggcaaat gggagagacc ctttgaagtc 600
aaggacaccg aggaagagga cttccacgtg gaccaggtga ccaccgtgaa ggtgcctatg 660
atgaagcgtt taggcatgtt taacatccag cactgtaaga agctgtccag ctgggtgctg 720
ctgatgaaat acctgggcaa tgccaccgcc atcttcttcc tgcctgatga ggggaaacta 780
cagcacctgg aaaatgaact cacccacgat atcatcacca agttcctgga aaatgaagac 840
agaaggtctg ccagcttaca tttacccaaa ctgtccatta ctggaaccta tgatctgaag 900
agcgtcctgg gtcaactggg catcactaag gtcttcagca atggggctga cctctccggg 960
gtcacagagg aggcacccct gaagctctcc aaggccgtgc ataaggctgt gctgaccatc 1020
gacgagaaag ggactgaagc tgctggggcc atgtttttag aggccatacc catgtctatc 1080
ccccccgagg tcaagttcaa caaacccttt gtcttcttaa tgattgacca aaataccaag 1140
tctcccctct tcatgggaaa agtggtgaat cccacccaaa aa 1182
<210> 41
<211> 394
<212> PRT
<213> Artificial Sequence
<220>
<223> Alpha-1 antitrypsine
<400> 41
Glu Asp Pro Gln Gly Asp Ala Ala Gln Lys Thr Asp Thr Ser His His
1 5 10 15
Asp Gln Asp His Pro Thr Phe Asn Lys Ile Thr Pro Asn Leu Ala Glu
20 25 30
Phe Ala Phe Ser Leu Tyr Arg Gln Leu Ala His Gln Ser Asn Ser Thr
35 40 45
Asn Ile Phe Phe Ser Pro Val Ser Ile Ala Thr Ala Phe Ala Met Leu
50 55 60
Ser Leu Gly Thr Lys Ala Asp Thr His Asp Glu Ile Leu Glu Gly Leu
65 70 75 80
Asn Phe Asn Leu Thr Glu Ile Pro Glu Ala Gln Ile His Glu Gly Phe
85 90 95
Gln Glu Leu Leu Arg Thr Leu Asn Gln Pro Asp Ser Gln Leu Gln Leu
100 105 110
Thr Thr Gly Asn Gly Leu Phe Leu Ser Glu Gly Leu Lys Leu Val Asp
115 120 125
Lys Phe Leu Glu Asp Val Lys Lys Leu Tyr His Ser Glu Ala Phe Thr
130 135 140
Val Asn Phe Gly Asp Thr Glu Glu Ala Lys Lys Gln Ile Asn Asp Tyr
145 150 155 160
Val Glu Lys Gly Thr Gln Gly Lys Ile Val Asp Leu Val Lys Glu Leu
165 170 175
Asp Arg Asp Thr Val Phe Ala Leu Val Asn Tyr Ile Phe Phe Lys Gly
180 185 190
Lys Trp Glu Arg Pro Phe Glu Val Lys Asp Thr Glu Glu Glu Asp Phe
195 200 205
His Val Asp Gln Val Thr Thr Val Lys Val Pro Met Met Lys Arg Leu
210 215 220
Gly Met Phe Asn Ile Gln His Cys Lys Lys Leu Ser Ser Trp Val Leu
225 230 235 240
Leu Met Lys Tyr Leu Gly Asn Ala Thr Ala Ile Phe Phe Leu Pro Asp
245 250 255
Glu Gly Lys Leu Gln His Leu Glu Asn Glu Leu Thr His Asp Ile Ile
260 265 270
Thr Lys Phe Leu Glu Asn Glu Asp Arg Arg Ser Ala Ser Leu His Leu
275 280 285
Pro Lys Leu Ser Ile Thr Gly Thr Tyr Asp Leu Lys Ser Val Leu Gly
290 295 300
Gln Leu Gly Ile Thr Lys Val Phe Ser Asn Gly Ala Asp Leu Ser Gly
305 310 315 320
Val Thr Glu Glu Ala Pro Leu Lys Leu Ser Lys Ala Val His Lys Ala
325 330 335
Val Leu Thr Ile Asp Glu Lys Gly Thr Glu Ala Ala Gly Ala Met Phe
340 345 350
Leu Glu Ala Ile Pro Met Ser Ile Pro Pro Glu Val Lys Phe Asn Lys
355 360 365
Pro Phe Val Phe Leu Met Ile Asp Gln Asn Thr Lys Ser Pro Leu Phe
370 375 380
Met Gly Lys Val Val Asn Pro Thr Gln Lys
385 390
<210> 42
<211> 394
<212> PRT
<213> Artificial Sequence
<220>
<223> Alpha-1 antitrypsine variant
<400> 42
Glu Asp Pro Gln Gly Asp Ala Ala Asn Lys Thr Asp Thr Ser His His
1 5 10 15
Asp Gln Asp His Pro Thr Phe Asn Lys Ile Thr Pro Asn Leu Ala Glu
20 25 30
Phe Ala Phe Ser Leu Tyr Arg Gln Leu Ala His Gln Ser Asn Ser Thr
35 40 45
Asn Ile Phe Phe Ser Pro Val Ser Ile Ala Thr Ala Phe Ala Met Leu
50 55 60
Ser Leu Gly Thr Lys Ala Asp Thr His Asp Glu Ile Leu Glu Gly Leu
65 70 75 80
Asn Phe Asn Leu Thr Glu Ile Pro Glu Ala Gln Ile His Glu Gly Phe
85 90 95
Gln Glu Leu Leu Arg Thr Leu Asn Gln Pro Asp Ser Gln Leu Gln Leu
100 105 110
Thr Thr Gly Asn Gly Leu Phe Leu Ser Glu Gly Leu Lys Leu Val Asp
115 120 125
Lys Phe Leu Glu Asp Val Lys Lys Leu Tyr His Ser Glu Ala Phe Thr
130 135 140
Val Asn Phe Gly Asp Thr Glu Glu Ala Lys Lys Gln Ile Asn Asp Tyr
145 150 155 160
Val Glu Lys Gly Thr Gln Gly Lys Ile Val Asp Leu Val Lys Glu Leu
165 170 175
Asp Arg Asp Thr Val Phe Ala Leu Val Asn Tyr Ile Phe Phe Lys Gly
180 185 190
Lys Trp Glu Arg Pro Phe Glu Val Lys Asp Thr Glu Glu Glu Asp Phe
195 200 205
His Val Asp Gln Val Thr Thr Val Lys Val Pro Met Met Lys Arg Leu
210 215 220
Gly Met Phe Asn Ile Gln His Cys Lys Lys Leu Ser Ser Trp Val Leu
225 230 235 240
Leu Met Lys Tyr Leu Gly Asn Ala Thr Ala Ile Phe Phe Leu Pro Asp
245 250 255
Glu Gly Lys Leu Gln His Leu Glu Asn Glu Leu Thr His Asp Ile Ile
260 265 270
Thr Lys Phe Leu Glu Asn Glu Asp Arg Arg Ser Ala Ser Leu His Leu
275 280 285
Pro Lys Leu Ser Ile Thr Gly Thr Tyr Asp Leu Lys Ser Val Leu Gly
290 295 300
Gln Leu Gly Ile Thr Lys Val Phe Ser Asn Gly Ala Asp Leu Ser Gly
305 310 315 320
Val Thr Glu Glu Ala Pro Leu Lys Leu Ser Lys Ala Val His Lys Ala
325 330 335
Val Leu Thr Ile Asp Glu Lys Gly Thr Glu Ala Ala Gly Ala Met Phe
340 345 350
Leu Glu Ala Ile Pro Met Ser Ile Pro Pro Glu Val Lys Phe Asn Lys
355 360 365
Pro Phe Val Phe Leu Met Ile Asp Gln Asn Thr Lys Ser Pro Leu Phe
370 375 380
Met Gly Lys Val Val Asn Pro Thr Gln Lys
385 390
<210> 43
<211> 1755
<212> DNA
<213> Artificial Sequence
<220>
<223> phGH-AT9N DNA
<400> 43
ttcccaacca ttcccttatc caggcttttt gacaacgcta tgctccgcgc ccatcgtctg 60
caccagctgg cctttgacac ctaccaggag tttgaagaag cctatatccc aaaggaacag 120
aagtattcat tcctgcagaa cccccagacc tccctctgtt tctcagagtc tattccgaca 180
ccctccaaca gggaggaaac acaacagaaa tccaacctag agctgctccg catctccctg 240
ctgctcatcc agtcgtggct ggagcccgtg cagttcctca ggagtgtctt cgccaacagc 300
ctggtgtacg gcgcctctga cagcaacgtc tatgacctcc taaaggacct agaggaaggc 360
atccaaacgc tgatggggag gctggaagat ggcagccccc ggactgggca gatcttcaag 420
cagacctaca gcaagttcga cacaaactca cacaacgatg acgcactact caagaactac 480
gggctgctct actgcttcag gaaggacatg gacaaggtcg agacattcct gcgcatcgtg 540
cagtgccgct ctgtggaggg cagctgtggc ttcgaggatc cccagggaga tgctgccaac 600
aagacagata catcccacca tgatcaggat cacccaacct tcaacaagat cacccccaac 660
ctggctgagt tcgccttcag cctataccgc cagctggcac accagtccaa cagcaccaat 720
atcttcttct ccccagtgag catcgctaca gcctttgcaa tgctctccct ggggaccaag 780
gctgacactc acgatgaaat cctggagggc ctgaatttca acctcacgga gattccggag 840
gctcagatcc atgaaggctt ccaggaactc ctccataccc tcaaccagcc agacagccag 900
ctccagctga ccaccggcaa tggcctgttc ctcagcgagg gcctgaagct agtggataag 960
tttttggagg atgttaaaaa gttgtaccac tcagaagcct tcactgtcaa cttcggggac 1020
accgaagagg ccaagaaaca gatcaacgat tacgtggaga agggtactca agggaaaatt 1080
gtggatttgg tcaaggagct tgacagagac acagtttttg ctctggtgaa ttacatcttc 1140
tttaaaggca aatgggagag accctttgaa gtcaaggaca ccgaggaaga ggacttccac 1200
gtggaccagg tgaccaccgt gaaggtgcct atgatgaagc gtttaggcat gtttaacatc 1260
cagcactgta agaagctgtc cagctgggtg ctgctgatga aatacctggg caatgccacc 1320
gccatcttct tcctgcctga tgaggggaaa ctacagcacc tggaaaatga actcacccac 1380
gatatcatca ccaagttcct ggaaaatgaa gacagaaggt ctgccagctt acatttaccc 1440
aaactgtcca ttactggaac ctatgatctg aagagcgtcc tgggtcaact gggcatcact 1500
aaggtcttca gcaatggggc tgacctctcc ggggtcacag aggaggcacc cctgaagctc 1560
tccaaggccg tgcataaggc tgtgctgacc atcgacgaga aagggactga agctgctggg 1620
gccatgtttt tagaggccat acccatgtct atcccccccg aggtcaagtt caacaaaccc 1680
tttgtcttct taatgattga ccaaaatacc aagtctcccc tcttcatggg aaaagtggtg 1740
aatcccaccc aaaaa 1755
<210> 44
<211> 394
<212> PRT
<213> Artificial Sequence
<220>
<223> Alpha-1 antitrypsine divariant
<400> 44
Glu Asp Pro Gln Gly Asp Ala Ala Asn Lys Thr Asp Thr Ser His His
1 5 10 15
Asp Gln Asp His Pro Thr Phe Asn Lys Ile Thr Pro Asn Leu Ala Glu
20 25 30
Phe Ala Phe Ser Leu Tyr Arg Gln Leu Ala His Gln Ser Asn Ser Thr
35 40 45
Asn Ile Phe Phe Ser Pro Val Ser Ile Ala Thr Ala Phe Ala Met Leu
50 55 60
Ser Leu Gly Thr Lys Ala Asp Thr His Asp Glu Ile Leu Glu Gly Leu
65 70 75 80
Asn Phe Asn Leu Thr Glu Ile Pro Glu Ala Gln Ile His Glu Gly Phe
85 90 95
Gln Glu Leu Leu Arg Thr Leu Asn Gln Pro Asp Ser Gln Leu Gln Leu
100 105 110
Thr Thr Gly Asn Gly Leu Phe Leu Ser Glu Gly Leu Lys Leu Val Asp
115 120 125
Lys Phe Leu Glu Asp Val Lys Lys Leu Tyr His Ser Glu Ala Phe Thr
130 135 140
Val Asn Phe Gly Asp Thr Glu Glu Ala Lys Lys Gln Ile Asn Asp Tyr
145 150 155 160
Val Glu Lys Gly Thr Gln Gly Lys Ile Val Asp Leu Val Lys Glu Leu
165 170 175
Asp Arg Asp Thr Val Phe Ala Leu Val Asn Tyr Ile Phe Phe Lys Gly
180 185 190
Lys Trp Glu Arg Pro Phe Glu Val Lys Asp Thr Glu Glu Glu Asp Phe
195 200 205
His Val Asp Gln Val Thr Thr Val Lys Val Pro Met Met Lys Arg Leu
210 215 220
Gly Met Phe Asn Ile Gln His Cys Lys Lys Leu Ser Ser Trp Val Leu
225 230 235 240
Leu Met Lys Tyr Leu Gly Asn Ala Thr Ala Ile Phe Phe Leu Pro Asp
245 250 255
Glu Gly Lys Leu Gln His Leu Glu Asn Glu Leu Thr His Asp Ile Ile
260 265 270
Thr Lys Phe Leu Glu Asn Glu Asp Arg Arg Ser Ala Ser Leu His Leu
275 280 285
Pro Lys Leu Ser Ile Thr Gly Thr Tyr Asp Leu Lys Ser Val Leu Gly
290 295 300
Gln Leu Gly Ile Thr Lys Val Phe Ser Asn Gly Ala Asp Leu Ser Gly
305 310 315 320
Val Thr Glu Glu Ala Pro Leu Lys Leu Ser Lys Ala Val His Lys Ala
325 330 335
Val Leu Thr Ile Asp Glu Lys Gly Thr Glu Ala Ala Gly Ala Met Phe
340 345 350
Leu Glu Ala Ile Asn Met Ser Ile Pro Pro Glu Val Lys Phe Asn Lys
355 360 365
Pro Phe Val Phe Leu Met Ile Asp Gln Asn Thr Lys Ser Pro Leu Phe
370 375 380
Met Gly Lys Val Val Asn Pro Thr Gln Lys
385 390
<210> 45
<211> 1706
<212> DNA
<213> Artificial Sequence
<220>
<223> pT603N
<400> 45
ccacccccct gggccctgcc agctccctgc cccagagctt cctgctcaag tgcttagagc 60
aagtgaggaa gatccagggc gatggcgcag cgctccagga gaagctgtgt gccacctaca 120
agctgtgcca ccccgaggag ctggtgctgc tcggacactc tctgggcatc ccctgggctc 180
ccctgagcag ctgccccagc caggccctgc agctggcagg ctgcttgagc caactccata 240
gcggcctttt cctctaccag gggctcctgc aggccctgga agggatctcc cccgagttgg 300
gtcccacctt ggacacactg cagctggacg tcgccgactt tgccaccacc atctggcagc 360
agatggaaga actgggaatg gcccctgccc tgcagcccac ccagggtgcc atgccggcct 420
tcgcctctgc tttccagcgc cgggcaggag gggtcctggt tgcctcccat ctgcagagct 480
tcctggaggt gtcgtaccgc gttctacgcc accttgccca gcccgaggat ccccagggag 540
atgctgccaa caagacagat acatcccacc atgatcagga tcacccaacc ttcaacaaga 600
tcacccccaa cctggctgag ttcgccttca gcctataccg ccagctggca caccagtcca 660
acagcaccaa tatcttcttc tccccagtga gcatcgctac agcctttgca atgctctccc 720
tggggaccaa ggctgacact cacgatgaaa tcctggaggg cctgaatttc aacctcacgg 780
agattccgga ggctcagatc catgaaggct tccaggaact cctccatacc ctcaaccagc 840
cagacagcca gctccagctg accaccggca atggcctgtt cctcagcgag ggcctgaagc 900
tagtggataa gtttttggag gatgttaaaa agttgtacca ctcagaagcc ttcactgtca 960
acttcgggga caccgaagag gccaagaaac agatcaacga ttacgtggag aagggtactc 1020
aagggaaaat tgtggatttg gtcaaggagc ttgacagaga cacagttttt gctctggtga 1080
attacatctt ctttaaaggc aaatgggaga gaccctttga agtcaaggac accgaggaag 1140
aggacttcca cgtggaccag gtgaccaccg tgaaggtgcc tatgatgaag cgtttaggca 1200
tgtttaacat ccagcactgt aagaagctgt ccagctgggt gctgctgatg aaatacctgg 1260
gcaatgccac cgccatcttc ttcctgcctg atgaggggaa actacagcac ctggaaaatg 1320
aactcaccca cgatatcatc accaagttcc tggaaaatga agacagaagg tctgccagct 1380
tacatttacc caaactgtcc attactggaa cctatgatct gaagagcgtc ctgggtcaac 1440
tgggcatcac taaggtcttc agcaatgggg ctgacctctc cggggtcaca gaggaggcac 1500
ccctgaagct ctccaaggcc gtgcataagg ctgtgctgac catcgacgag aaagggactg 1560
aagctgctgg ggccatgttt ttagaggcca taaacatgtc tatccccccc gaggtcaagt 1620
tcaacaaacc ctttgtcttc ttaatgattg accaaaatac caagtctccc ctcttcatgg 1680
gaaaagtggt gaatcccacc caaaaa 1706
Claims (7)
- α−1アンチトリプシンのN−末端の1番位置から25番位置の間の特定部位にあるアミノ酸をアスパラギンに置換して糖化部位を追加させたことを特徴とするα−1アンチトリプシン変異体であって、
該特定部位は、9番位置あるいは12番位置である、α−1アンチトリプシン変異体。 - a) α−1アンチトリプシンのN−末端の9番位置あるいは12番位置にあるアミノ酸をアスパラギンに置換して糖化部位を追加させる段階と、
b) 前記糖化部位が追加されたα−1アンチトリプシン発現ベクターを転移させた細胞を培地上で培養する段階と、
c) 前記細胞からα−1アンチトリプシン変異体タンパク質を発現させる段階と、
d) 前記発現されたα−1アンチトリプシン変異体タンパク質を精製して回収する段階と、
を含むことを特徴とする、請求項1に記載のα−1アンチトリプシン変異体の製造方法。 - 請求項1に記載のα−1アンチトリプシン変異体を有効成分で含むことを特徴とするα−1アンチトリプシン欠乏症の予防または治療用組成物。
- 前記α−1アンチトリプシン欠乏症は、慢性閉鎖性肺疾患あるいは肝硬変であることを特徴とする請求項3に記載のα−1アンチトリプシン欠乏症の予防または治療用組成物。
- 請求項1に記載のα−1アンチトリプシン変異体を二つ連結して体内半減期が増加されたことを特徴とするα−1アンチトリプシン変異体の融合体。
- 請求項1に記載のα−1アンチトリプシン変異体に他の異種タンパク質を連結して異種タンパク質の体内半減期が増加されたことを特徴とするα−1アンチトリプシン変異体の融合体。
- 前記α−1アンチトリプシン変異体は、追加的にP2位置である、α−1アンチトリプシンのN−末端の357番目アミノ酸のプロリン (proline)がアスパラギン(asparagine)に置換されたことを特徴とする請求項6に記載のα−1アンチトリプシン変異体の融合体。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110092819 | 2011-09-15 | ||
KR10-2011-0092819 | 2011-09-15 | ||
KR10-2012-0058998 | 2012-06-01 | ||
KR1020120058998A KR101402702B1 (ko) | 2011-09-15 | 2012-06-01 | 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 |
PCT/KR2012/006441 WO2013039295A1 (ko) | 2011-09-15 | 2012-08-13 | 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014534166A JP2014534166A (ja) | 2014-12-18 |
JP6001074B2 true JP6001074B2 (ja) | 2016-10-05 |
Family
ID=48179554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014530581A Active JP6001074B2 (ja) | 2011-09-15 | 2012-08-13 | 新規なα−1アンチトリプシン変異体、その製造方法及び用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9051395B2 (ja) |
EP (1) | EP2757110B1 (ja) |
JP (1) | JP6001074B2 (ja) |
KR (1) | KR101402702B1 (ja) |
CN (1) | CN103827141B (ja) |
AU (1) | AU2012309292B2 (ja) |
BR (1) | BR112014005788B1 (ja) |
CA (1) | CA2848919C (ja) |
MX (1) | MX349364B (ja) |
RU (1) | RU2567007C1 (ja) |
WO (1) | WO2013039295A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013183948A1 (ko) | 2012-06-05 | 2013-12-12 | 씨제이제일제당 (주) | 고당화된 지속형 인간 성장호르몬 단백질 및 이의 제조방법 |
WO2019125002A1 (ko) | 2017-12-20 | 2019-06-27 | (주)알테오젠 | 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질 |
KR102167827B1 (ko) * | 2017-12-20 | 2020-10-20 | 주식회사 알테오젠 | 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질 |
WO2019237079A2 (en) * | 2018-06-07 | 2019-12-12 | Xiaolong Zhang | Pharmaceutical composition containing fusion protein and use thereof |
KR102134571B1 (ko) * | 2018-06-15 | 2020-07-16 | 주식회사 알테오젠 | 혈액응고인자 VII/VIIa 융합단백질의 제조 방법 |
SG11202012765PA (en) | 2018-06-22 | 2021-01-28 | Ucl Business Ltd | Novel compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0133252B1 (ko) * | 1993-05-18 | 1998-04-14 | 김은영 | 내열성의 알파-1-안티트립신 뮤테인 |
US5817484A (en) * | 1993-05-18 | 1998-10-06 | Korea Institute Of Science And Technology | Thermoresistant α-1-antitrypsin mutein |
RU2392963C2 (ru) * | 2004-08-09 | 2010-06-27 | Элиоз Байофарма, Инк. | Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов |
EP2167539A2 (en) | 2007-06-15 | 2010-03-31 | Charite-Universitätsmedizin Berlin | Methods for producing glycosylated human alpha-1 antitrypsin (a1at) in mammalian host cells |
BRPI1006443B1 (pt) * | 2009-04-22 | 2021-05-25 | Alteogen, Inc | Proteína ou peptídeo de fusão e método para aumentar a meia-vida in vivo de uma proteína ou peptídeo |
WO2013183948A1 (ko) * | 2012-06-05 | 2013-12-12 | 씨제이제일제당 (주) | 고당화된 지속형 인간 성장호르몬 단백질 및 이의 제조방법 |
-
2012
- 2012-06-01 KR KR1020120058998A patent/KR101402702B1/ko active IP Right Grant
- 2012-08-13 CA CA2848919A patent/CA2848919C/en active Active
- 2012-08-13 BR BR112014005788-5A patent/BR112014005788B1/pt active IP Right Grant
- 2012-08-13 AU AU2012309292A patent/AU2012309292B2/en active Active
- 2012-08-13 MX MX2014003183A patent/MX349364B/es active IP Right Grant
- 2012-08-13 JP JP2014530581A patent/JP6001074B2/ja active Active
- 2012-08-13 US US14/344,468 patent/US9051395B2/en active Active
- 2012-08-13 WO PCT/KR2012/006441 patent/WO2013039295A1/ko active Application Filing
- 2012-08-13 RU RU2014114790/10A patent/RU2567007C1/ru active
- 2012-08-13 CN CN201280044912.8A patent/CN103827141B/zh active Active
- 2012-08-13 EP EP12831806.0A patent/EP2757110B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9051395B2 (en) | 2015-06-09 |
MX2014003183A (es) | 2015-01-12 |
KR101402702B1 (ko) | 2014-06-05 |
RU2014114790A (ru) | 2015-10-20 |
BR112014005788B1 (pt) | 2021-01-12 |
CA2848919C (en) | 2016-09-13 |
US20140371160A1 (en) | 2014-12-18 |
AU2012309292B2 (en) | 2015-05-07 |
AU2012309292A1 (en) | 2014-04-24 |
JP2014534166A (ja) | 2014-12-18 |
RU2567007C1 (ru) | 2015-10-27 |
WO2013039295A1 (ko) | 2013-03-21 |
KR20130029713A (ko) | 2013-03-25 |
CN103827141A (zh) | 2014-05-28 |
MX349364B (es) | 2017-07-26 |
EP2757110A4 (en) | 2015-04-22 |
CN103827141B (zh) | 2016-01-13 |
CA2848919A1 (en) | 2013-03-21 |
EP2757110A1 (en) | 2014-07-23 |
EP2757110B1 (en) | 2017-09-27 |
BR112014005788A2 (pt) | 2017-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6001074B2 (ja) | 新規なα−1アンチトリプシン変異体、その製造方法及び用途 | |
AU650730B2 (en) | Recombinant human factor VIII derivatives | |
AU2010244592B2 (en) | Recombinant human alpha1-antitrypsin | |
JP2019531087A (ja) | 高グリコシル化ヒト血液凝固第viii因子の融合タンパク質、その調製方法、および使用 | |
JP2010518039A (ja) | カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用 | |
AU2021225156B2 (en) | UTI fusion proteins | |
TWI835773B (zh) | 組合物及使用方法 | |
US20240132573A1 (en) | Modified serpins for the treatment of bradykinin-mediated disease | |
HUT75358A (en) | Methods of prouducing effective recombinant serine protease inhibitors and uses of these inhibitors | |
EP3858865A9 (en) | Fusion protein of mutated single-chain human coagulation factor viii, preparation method therefor, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160818 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160831 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6001074 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |